Haematology News and Research

RSS

Study: Brain tumors hijack the brain's existing blood supply during progression

Dangerous brain tumors hijack the brain's existing blood supply throughout their progression, by growing only within narrow potential spaces between and along the brain's thousands of small blood vessels, new research shows for the first time.

12 Aug 2014

5-LO enzyme plays important role in the survival of leukaemic AML stem cells

Despite improved therapy, only one out of every two adult patients survive acute myeloid leukaemia (AML). The mean survival time for this disease, which predominantly occurs in the elderly, is less than a year for patients over 65 years. It is assumed that leukaemic stem cells, which cannot be completely eliminated during treatment, are the origin of relapse.

4 Aug 2014

Sigma-Tau Rare Disease seeks EMA approval for use of Oncaspar for ALL treatment

Sigma Tau Pharma Ltd. (hereinafter referred to as Sigma-Tau Rare Disease), today announced the submission of an application to the European Medicines Agency for use of its pegylatedL-asparaginase, Oncaspar (pegaspargase) for the treatment of Acute Lymphoblastic Leukaemia (ALL) as part of a multi-agent chemotherapeutic regimen.

10 Jul 2014

Beckman Coulter Life Sciences launches Aquios CL Clinical Flow Cytometer* for laboratory use

Beckman Coulter Life Sciences is set to transform the use of flow cytometry in the routine clinical laboratory with its latest offering, the Aquios CL Clinical Flow Cytometer*. Fully automated, with a small footprint, the instrument is the first authentic ‘LOAD & GO’ cytometry system.

13 Jun 2014

EMA recommends marketing authorisation for Octapharma’s human cell line recombinant human FVIII, Nuwiq

Octapharma confirmed today the European Medicines Agency (EMA) has adopted a positive opinion towards human cell line recombinant human FVIII, Nuwiq®, recommending the granting of a marketing authorisation for the medicinal product for treatment and prophylaxis of bleeding (also during and after surgery) in paediatric and adult patients with haemophilia A (congenital FVIII deficiency).

27 May 2014

Cell Therapeutics announces launch of PIXUVRI in the UK for treatment of aggressive B-cell NHL

Cell Therapeutics, Inc. today announced the launch of PIXUVRI (pixantrone), the first new treatment for adult patients in the United Kingdom (UK) with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (aggressive B-cell NHL), at the 54th annual scientific meeting of the British Society for Haematology.

29 Apr 2014

Australian and New Zealand patients with diabetes-induced vision loss to get access to new treatment

Australian and New Zealand patients suffering from vision impairment due to a type of diabetes-induced eye disease will have access to a new treatment, following a license deal between Australian biopharmaceutical company Specialised Therapeutics Australia and Alimera Sciences.

28 Apr 2014

Genetic evidence confirms role of group of virus-fighting genes in cancer development

Researchers have found a major piece of genetic evidence that confirms the role of a group of virus-fighting genes in cancer development.

15 Apr 2014

New drug for patients with leukaemia and lymphoma puts an end to chemotherapy

Patients with terminal forms of leukaemia and lymphoma who have run out of treatment options could soon benefit from a new drug, which not only puts an end to chemotherapy and has virtually no side effects but also improves a patient's life expectancy and quality of life.

20 Mar 2014

CLL patients more prone to infections due to reduced number of antibodies

People with chronic lymphocytic leukaemia (CLL) are essentially more prone to infections such as varicella, influenza or pneumococci due to the reduction in the number of antibodies that their condition causes.

19 Mar 2014

Researchers identify two novel genes associated with development of rare, aggressive blood cancer

Researchers have identified two novel cancer genes that are associated with the development of a rare, highly aggressive, cancer of blood vessels. These genes may now act as markers for future treatments and explain why narrowly targeted therapies that are directed at just one target fail.

17 Mar 2014

Researchers investigate stickiness of leukaemia cells and its link to drug resistance

Researchers in Manchester have investigated the stickiness of leukaemia cells, and whether this is linked to drug resistance.

11 Mar 2014

Oxford Gene Technology announces acquisition of Cytocell

Oxford Gene Technology, a provider of innovative genetics research solutions, today announced the acquisition of Cambridge-based Cytocell Limited, a leading provider of DNA technology for the detection of gene rearrangements related to inherited genetic disease and cancer.

From Oxford Gene Technology 4 Mar 2014

Report calls for better palliative and EOL care for patients that relapse following transplant

Haematological disorders of the blood and bone marrow, such as leukaemia, are commonly treated with a bone marrow transplant. However relapse is common and often leads to treatment failure and death.

26 Feb 2014

CTI announces initiation of pacritinib Phase 2 trial in AML patients with FLT3 mutations

Cell Therapeutics, Inc. today announced the initiation of an international cooperative group Phase 2 clinical trial of pacritinib in adult patients with relapsed acute myeloid leukemia (AML) with mutations of the FLT3 gene. Mutation of the FLT3 gene is found in approximately one-third of AML patients and is an independent risk factor for poor prognosis.

30 Jan 2014

Elsevier launches open access journal, Pathogenesis

Elsevier, world-leading provider of scientific, technical and medical information products and services, announces the launch of open access journal, Pathogenesis.

29 Jan 2014

Scientists develop novel treatment for Hairy Cell Leukaemia using drug administered to combat skin cancer

A team of scientists from the University of Leicester has demonstrated a novel treatment for Hairy Cell Leukaemia (HCL), a rare type of blood cancer, using a drug administered to combat skin cancer.

16 Jan 2014

NICE issues Final Appraisal Determination for PIXUVRI (pixantrone) drug

Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today reported that the National Institute for Health and Care Excellence (NICE), the independent body responsible for driving improvement and excellence in the health and social care system in the United Kingdom (UK), has issued its Final Appraisal Determination (FAD) for PIXUVRI® (pixantrone).

6 Jan 2014

Studies confirm superiority of Tasigna to Glivec at achieving molecular response in Ph+ CML patients

Findings from three large, randomized Phase III studies demonstrate the superiority of Tasigna (nilotinib) compared to Glivec (imatinib) at achieving deeper molecular responses across various Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) patient populations, including newly diagnosed patients, patients with residual disease who switched to Tasigna after long-term treatment with Glivec, and patients who failed to respond to frontline Glivec (as defined by 2013 European LeukemiaNet [ELN] guidelines).

9 Dec 2013

Patrys to present data from PAT-SM6 Phase I/IIa trial in multiple myeloma at ASH conference

Patrys Limited (ASX: PAB), a clinical stage biotechnology company has announced that updated results from its PAT-SM6 Phase I/IIa clinical trial in multiple myeloma will be presented at the 55th American Society of Hematology Annual Meeting in New Orleans, LA on 7- 10 December 2013.

29 Nov 2013